short-right-arrow logoMobile media-pie 1 7 % share download email linkedin round-download

Privacy Preference Centre

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. We use two types of cookies on our website: cookies which are necessary for this website to function and analytics cookies. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies used

  • CookieNotice
  • CookieAnalytics

Analytics Cookies

These are Google Analytics cookies which allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site and social media platforms All information these cookies collect is aggregated and therefore anonymous. This cookie is defaulted to ‘Active’, which means we will be able to track, on any anonymous basis, how many visitors we have to our site, and monitor its performance. If you wish to turn them off you can do so by unticking ‘Active’ and clicking ‘Save and Accept Cookies’. For more information on how these cookies work, including a link through to the Google Privacy Policy which sets out further information about data which Google may collect in the course of providing us with Analytics.

Cookies used

  • _ga

Targeting Cookies

We use necessary cookies to make our site work. We also use analytics cookies which collect information about how visitors use our website and help us to improve it; these are defaulted to ‘Active’, if you wish to turn them off you can do so through the Cookie Settings. Please be aware that by blocking some types of cookies it may impact your experience of the site and the services we are able to offer. For more information about any of these cookies and our use of them, or to change your settings at any time, please see Cookie Settings and our Cookies Policy.

Bridgepoint in the News

12 November 2021

Bridgepoint to sell HTL

Montagu, a leading European private equity firm, has entered into exclusive negotiations with Bridgepoint, to acquire HTL Biotechnology (“HTL” or “the company”), an international, fast-growing biotech and industrial firm leading the development and production of innovative pharmaceutical grade biopolymers. Financial terms of the transaction are not being disclosed.

Founded in 1992, HTL has developed a state-of-the-art biopolymers platform which provides customised, pharmaceutical grade biopolymer solutions to leading pharmaceutical and medical device companies worldwide. Its products are used in therapeutic areas such as ophthalmology, rheumatology, urology, dermatology, and medical aesthetics. The company is recognised as the world pioneer in industrialising the bioproduction of hyaluronic acid.

Montagu’s deep sector expertise coupled with the company’s strong healthcare capabilities and organisational foundation will enable HTL to consolidate its global leadership and continue to provide exceptional value to its clients and end-users.

Yvon Bastard, CEO of HTL, commented, “We look forward to partnering with Montagu. Their extensive experience in the healthcare field, will allow us to accelerate our growth, continue to innovate, and realise our international ambitions.”

Guillaume Jabalot, Director at Montagu, said: “HTL represents several key features of a Montagu deal, demonstrating a competitive and defensible core business in an attractive market. The management team has accelerated growth and innovation through R&D, which have reinforced the company’s leadership position globally and opened new growth avenues. We are proud to be partnering with HTL and its employees and supporting them in being at the forefront of innovation in the biopolymers sector and improving patients’ lives.”

Vincent-Gael Baudet, Partner, Bridgepoint, said: “We’re delighted to have worked with the HTL management team to drive the transition of the company to become a biotechnology platform of scale, and a leading R&D partner to pharmaceutical companies across the world. We wish the management team every success as they embark on the next exciting chapter.”


Contact us

If you are interested in working for Bridgepoint, please complete the form below.


Investor reports registration

To access investor reports through the web based reporting facility, please fill in the form to register for an account.

The information submitted on this form will be used for the sole purpose of registering you as an account user and will not be shared with third parties.


Request a copy of The Point

Mandatory fields are marked as (required*)